FDA partner Julie Tibbets highlights the growing need for companies, showcasing innovative and marketed drug products at large medical meetings, to beware of the U.S. Food and Drug Administration’s Office of Prescription Drug Promotion increased efforts targeting and enforcing exhibit booth content in recent years.
Read the full article.
Related Content
- InsightOctober 13, 2023
FDA’s Proposed Rule for Oversight of Laboratory Developed Tests: Part II: FDA’s Proposed Phaseout Policy – Key Considerations & Open Questions
- InsightOctober 6, 2023
FDA’s Proposed Rule for Oversight of Laboratory Developed Tests: Part I: Underpinnings of FDA’s Proposed Rule
- AlertSeptember 15, 2023
Modernizing the FDA’s 510(k) Program for Medical Devices: Selection of Predicate Devices and Use of Clinical Data in 510(k) Submissions
- InsightJune 29, 2023
A Look Ahead in Life Sciences: What We Are Tracking in Q3 2023 and Beyond
- InsightMay 24, 2023
Top IP, FDA, and Compliance Issues for Medtech Companies Transitioning to Data-Enabled Product Solutions
- AlertApril 5, 2023
CMS Issues Guidance and Solicits Comment on the 2026 Inflation Reduction Act Part D Negotiation Process
- AlertMarch 15, 2023
The Long (Un)Winding Road: FDA Maps Out How the End of the Public Health Emergency Will Impact its COVID-19 Policies
- InsightMarch 2, 2023
A Recap of Resilience: Goodwin’s Life Sciences Practice
- Press ReleaseNovember 16, 2023
Pathology Watch to be Acquired by Sonic Healthcare
- Press ReleaseNovember 2, 2023
Goodwin Represents the Initial Purchasers and Dealers on Enovis Corporation’s $460 million 3.875% Convertible Senior Notes Offering and Capped Call
- Press ReleaseNovember 2, 2023
Goodwin Represents the Initial Purchasers and Dealers on Amphastar Pharmaceuticals, Inc.’s $345 million 2.00% Convertible Senior Notes Offering
- Speaking EngagementsOctober 24, 2023
3rd Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA
- Press ReleaseOctober 5, 2023
Orchard Therapeutics To Be Acquired By Kyowa Kirin For $387 Million and Contingent Value Rights
- Press ReleaseOctober 4, 2023
Teva and Sanofi Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment, with $500 Million Upfront and up to $1 Billion in Milestones
- Awards and RankingsOctober 2, 2023
Matt Wetzel Named the 2023 Patricia T. Meador Leadership Award Recipient by the American Health Law Association
- Press ReleaseSeptember 8, 2023
Seagen and Nurix Enter Into Strategic Collaboration for $60 Million Upfront and up to $3.4 Billion in Milestones to Develop New Class of Cancer Drugs